The Behaviour of Various Platelet Function Tests During Long-Term Prostacyclin Infusion in Patients with Peripheral Vascular Disease

Summary

In 20 patients with peripheral vascular disease treated with prostacyclin (5 ng/kg/min) we observed a significant activation of platelet function as measured by platelet proteins, ADP- induced aggregation platelet sensitivity and platelet count. Only the platelet survival was significantly prolonged by the treatment.

Keywords

Prostacyclin treatment - Platelet survival - Platelet proteins - ADP-induced aggregation - Platelet sensitivity antiaggregatory prostaglandins - Peripheral vascular disease

• References

• 1 Szczeklik A, Gryglewski R, Nizankowski R, Skawinski J, Gluszko P, Korbut R. Prostacyclin therapy in peripheral arterial disease. Thromb Res 1979; 19: 191-199
• 2 Szczeklik A, Nizankowski R, Skawinski J, Szczeklik J, Gluszko P, Gryglewski RJ. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1979; 1: 1111-1114
• 3 Carlson LA, Olsson AG. Intravenous prostaglandin E₁ in severe peripheral vascular disease. Lancet 1976; 2: 810
• 4 Machin SJ, Chamone PA, Defreyn G, Vermylen J. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto-PGF₁ alpha levels. Br J Haematol 1981; 47: 413-422
• 5 Olsson AG, Nilsson E. The effect of intravenous prostacyclin on resting pains and healing of ischemic ulcers in peripheral artery disease. Prostaglandins Med 1981; 6: 329-339
• 6 Silberbauer K, Sinzinger H, Schemthaner G, Leithner Ch, Kaliman J, Elliott M, Burghuber O. Prostacyclin infusion in men: effects on hormones and on cardiovascular system. Prostaglandins Thrombo-xanes 1980; 2: 345-349
• 7 Silberbauer K, Sinzinger H, Punzengruber Ch. Long-term prostacy-clin (PGI₂)-therapy in peripheral arterial disease, influence on some vascular and platelet regulation mechanisms. In: Prostaglandins in Clinical Medicine, Cardiovascular and Thrombotic Disorders. Year-book Med Publishers; 1982. pp 182-191
• 8 Sinzinger H, Silberbauer K, Horsch AK, Gall A. Decreased sensitivity of human platelets to PGI₂ during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon. Prostaglandins 1981; 18: 56-58
• 9 Mühlhauser I, Schemthaner G, Silberbauer K, Kaliman J, Sinzinger H. Platelet specific proteins in atherosclerosis and related diseases. Artery 1981; 8: 47-55
• 10 Sinzinger H, Angelberger P, Kolbe H. Influence of incubation time and temperature on indium-111-oxine uptake by human platelets. Thromb Haemostas 1981; 45: 295
• 11 Siegl AM, Smith JB, Silver MJ, Nicolaou KC, Ahem D. Selective binding site for (³H)prostacyclin on platelets. J Clin Invest 1979; 63: 215-220